Today it was reported that a Director at Jazz Pharmaceuticals (NASDAQ: JAZZ), Rick Winningham, exercised options to sell 16,639 JAZZ shares at $64.29 a share, for a total transaction value of $2.93M.
Following Rick Winningham’s last JAZZ Sell transaction on August 14, 2017, the stock climbed by 35.9%.
See today’s analyst top recommended stocks >>
Based on Jazz Pharmaceuticals’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $500 million and quarterly net profit of $92.32 million. In comparison, last year the company earned revenue of $394 million and had a net profit of $106 million. JAZZ’s market cap is $10.64B and the company has a P/E ratio of 24.80. Currently, Jazz Pharmaceuticals has an average volume of 262.6K.
Based on 15 analyst ratings, the analyst consensus is Strong Buy with an average price target of $202.42, reflecting a -13.4% downside.
Rick Winningham’s trades have generated a -3.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.
